Apellis Pharmaceuticals

Yahoo Finance • 17 days ago

Sobi Receives Positive CHMP Opinion for Aspaveli® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN

Approximately 8,000 people in Europe are living with C3G or primary IC-MPGN If approved, Aspaveli (pegcetacoplan) would be the first C3G and primary IC-MPGN treatment for patients 12 and older STOCKHOLM, Dec. 12, 2025 /PRNewswire/ -- Sobi... Full story

Yahoo Finance • 25 days ago

The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

Robust and clinically meaningful benefits across all three key markers of disease – 68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of C3 deposits Consistent results across adolescent and adult pat... Full story

Yahoo Finance • last month

Mizuho Lowers Price Target on Apellis Pharmaceuticals (APLS) Amid Ongoing Eye Disease Therapy Challenges

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) ranks among the most oversold biotech stocks to invest in. On November 3, Mizuho maintained its Neutral rating for Apellis Pharmaceuticals Inc. (NASDAQ:APLS) and reduced its price target from $24... Full story

Yahoo Finance • last month

Cold Agglutinin Disease (CAD) Market Analysis, Business Prospects, Case Studies and Competitive Intelligence 2025-2035

Dublin, Nov. 14, 2025 (GLOBE NEWSWIRE) -- The "Cold Agglutinin Disease Market - A Global and Regional Analysis: Focus on Drug Class, Dosage Form, and Region - Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's... Full story

Yahoo Finance • 2 months ago

Caterpillar upgraded, Elf Beauty downgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: HSBC upgraded Caterpillar (CAT) to Buy... Full story

Yahoo Finance • 2 months ago

Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference

WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025 at 2:40 p.m. ET. The l... Full story

Yahoo Finance • 2 months ago

Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results

Generated $459 million in 3Q 2025 revenues, including $178 million in U.S. net product sales Received 152 new patient start forms for EMPAVELI® (pegcetacoplan) in the first two months since launch in C3G and primary IC-MPGN Reported EMPAVE... Full story

Yahoo Finance • 2 months ago

Here are the major earnings before the open Thursday

Major earnings expected before the bell on Thursday include: * Altria Group (MO [https://seekingalpha.com/symbol/MO]) * Merck & Co. (MRK [https://seekingalpha.com/symbol/MRK]) * Enterprise Products Partners L.P. (EPD [https://seekin... Full story

Yahoo Finance • 2 months ago

New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week

Significant proteinuria reduction maintained at one year, regardless of immunosuppressant use or baseline proteinuria levels Complete proteinuria remission (UPCR ≤0.5 g/g)achieved in one-third of patients and sustained through one yearTwo... Full story

Yahoo Finance • 2 months ago

First Week of December 19th Options Trading For Apellis Pharmaceuticals (APLS)

Investors in Apellis Pharmaceuticals Inc (Symbol: APLS) saw new options begin trading this week, for the December 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the APLS options chain for the new... Full story

Yahoo Finance • 2 months ago

Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results

Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 F, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference... Full story

Yahoo Finance • 3 months ago

Stocks Climb on Strength in Consumer Spending and Tame Inflation

The S&P 500 Index ($SPX) (SPY) today is up +0.56%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.81%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.28%.  December E-mini S&P futures (ESZ25) are up +0.53%, and December E-mini Nas... Full story

Yahoo Finance • 3 months ago

Apellis down as Goldman Sachs cuts to sell on risks to outlook

[Business on Wall Street in Manhattan] Pgiam/iStock via Getty Images Apellis Pharmaceuticals (NASDAQ:APLS [https://seekingalpha.com/symbol/APLS]) traded lower on Friday after Goldman Sachs downgraded the company to Sell from Neutral, citi... Full story

Yahoo Finance • 3 months ago

APLS Crosses Below Key Moving Average Level

In trading on Monday, shares of Apellis Pharmaceuticals Inc (Symbol: APLS) crossed below their 200 day moving average of $54.19, changing hands as low as $54.00 per share. Apellis Pharmaceuticals Inc shares are currently trading down abou... Full story

Yahoo Finance • 4 months ago

Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences

WALTHAM, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that management will participate in webcast fireside chats at the following investor conferences: Wells Fargo Healthcare Conf... Full story

Yahoo Finance • 5 months ago

APELLIS PHARMACEUTICALS INC (NASDAQ:APLS) Reports Mixed Q2 2025 Results with EPS Beat and Revenue Miss

APELLIS PHARMACEUTICALS INC (NASDAQ:APLS [https://www.chartmill.com/stock/quote/APLS]) reported its second-quarter 2025 financial results, revealing mixed performance relative to analyst expectations. The biopharmaceutical company posted r... Full story

Yahoo Finance • 5 months ago

Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results

Received U.S. FDA approval for EMPAVELI® (pegcetacoplan) for treatment of patients 12 years and older with C3G and primary IC-MPGN Announced capped royalty purchase agreement with Sobi under which Apellis receives up to $300 million for 90... Full story

Yahoo Finance • 5 months ago

Apellis wins FDA label expansion for Empaveli in rare kidney disorders

[Headquarters of US Food and Drug Administration (FDA)] Grandbrothers/iStock Editorial via Getty Images Apellis Pharmaceuticals (NASDAQ:APLS [https://seekingalpha.com/symbol/APLS]) announced on Tuesday that the U.S. FDA approved its injec... Full story

Yahoo Finance • 5 months ago

Apellis Pharma Secures FDA Approval For EMPAVELI To Treat Rare Kidney Disorders

(RTTNews) - Apellis Pharmaceuticals Inc. (APLS) announced that the U.S. Food and Drug Administration has approved EMPAVELI (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative g... Full story

Yahoo Finance • 5 months ago

FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older

Proven efficacy across all three key markers of disease—68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of C3 deposits Broad label includes adults and adolescents with C3G or primary IC-MPGN, and... Full story